Nimustine


Concise Prescribing Info
Indications/Uses
Malignant glioma.
Dosage/Direction for Use
Adult : IV 2-3 mg/kg as a single dose 6 wkly according to haematological response.
Dosage Details
Intravenous
Malignant glioma
Adult: As hydrochloride: 2-3 mg/kg or 90-100 mg/m2 as a single dose by slow IV inj at intervals of 6 wk according to haematological response.
Contraindications
Pregnancy and lactation.
Special Precautions
Child. Renal or hepatic impairment, haemorrhagic syndrome, infectious diseases. Monitor blood counts and liver function.
Adverse Reactions
Leukopenia, iron-deficiency anaemia, anorexia, nausea, vomiting, diarrhoea, stomatitis, headache, dizziness, convulsions, weakness, fatigue, haemorrhagic symptoms, interstitial pneumonitis, increased body temperature, alopecia, rash, increased transaminases.
Potentially Fatal: Delayed and cumulative bone marrow depression.
Drug Interactions
Additive bone marrow suppression with other cytotoxic drugs e.g. vincristine, doxorubicin, mitomycin.
Action
Description: Nimustine, a nitrosourea, is an alkylating antineoplastic agent. It interferes with normal DNA function by alkylating and cross-linking the strands of DNA and possibly by protein modification.
Disclaimer: This information is independently developed by MIMS based on Nimustine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in